Protagonist Therapeutics Secures $14,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3f35b463-c84f-4c18-ade4-e110e71544c8&Preview=1 - Date
6/5/2013 - Company Name
Protagonist Therapeutics - Mailing Address
1455 Adams Drive Menlo Park, CA 94025 - Company Description
Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable. - Website
http://www.protagonist-inc.com - Transaction Type
Venture Equity - Transaction Amount
$14,000,000 - Transaction Round
Series B - Proceeds Purposes
The new funding will support the discovery and development of Protagonist’s pipeline of oral di-sulfide rich peptide (DRP) therapeutics that combine the best properties of small molecule drugs and large molecule biologics in a single chemical entity. - M&A Terms
- Venture Investor
Johnson & Johnson Development Corporation - Venture Investor
Lilly Ventures - Venture Investor
Starfish Ventures
